Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction  by Chew, David K.W. et al.
From the Society for Vascular Surgery
Matrix metalloproteinase-specific inhibition of
Ca2 entry mechanisms of vascular contraction
David K. W. Chew, MD,a Michael S. Conte, MD,b and Raouf A. Khalil, MD, PhD,c West Roxbury and
Boston, Mass
Objective: Abdominal aortic aneurysm (AAA) is a common disease with as yet unclear cause. Increased matrix metallo-
proteinase (MMP) levels in the plasma and aorta are a consistent finding in AAA. Although the role of MMPs in AAA has
largely been attributed to degradation of the extracellular matrix proteins, the effects of MMPs on the mechanisms of
aortic contraction are unclear. The purpose of this study was to test the hypothesis that MMPs promote aortic dilation
by inhibiting the Ca2 mobilization mechanisms of smooth muscle contraction.
Methods: Isometric contraction and 45Ca2 influx were measured in aortic strips isolated from male Sprague-Dawley rats
treated or not treated with MMP-2 and MMP-9.
Results: In normal Krebs solution (2.5 mmol/L Ca2) phenylephrine (105 mol/L) caused contraction of the aortic
strips, which was significantly inhibited (P < .05) by MMP-2 (maximum, 48.9%  5.0%) and to a greater extent by
MMP-9 (maximum, 69.8%  6.2%). The MMP-induced inhibition of phenylephrine contraction depended on concen-
tration and time. The inhibitory effects of MMPs on phenylephrine contraction were reversible. In Ca2-free (2 mmol/L
ethylene glycol bis[-aminoethyl ether]-N,N,N=,N=-tetraacetic acid) Krebs solution phenylephrine caused a small
contraction that was not inhibited by MMP-2 or MMP-9, which suggests that MMPs do not inhibit Ca2 release from
the intracellular stores. Membrane depolarization with 96 mmol/L of potassium chloride, which stimulates Ca2 entry
from the extracellular space, caused a time-dependent and reversible contraction, which was inhibited by MMP-2 and
MMP-9. Histologic studies of MMP-treated tissues stained with hematoxylin-eosin or Verhoeff stain for elastin
confirmed the absence of degradation of the extracellular matrix. MMP-2 and MMP-9 also caused significant inhibition
of 45Ca2 influx induced by phenylephrine and potassium chloride.
Conclusions: These data suggest that MMP-2 and MMP-9 promote aortic dilation by inhibiting the Ca2 entry
mechanism of vascular smooth muscle contraction. (J Vasc Surg 2004;40:1001-10.)
Clinical Relevance: Abdominal aortic aneurysm (AAA) is a slow and progressive disease. The late stages of AAA are
characterized by degenerative changes in the extracellular matrix and smooth muscle components of the aortic wall. The
present study describes novel inhibitory effects of matrix metalloproteinase (MMP) on the Ca2 entry mechanisms of
aortic smooth muscle contraction, even in the absence of extracellular matrix degradation. The MMP-induced inhibition
of aortic contraction may further explain the role of increased MMP activity particularly during the early development of
AAA. Chronic exposure toMMPs may lead to protracted inhibition of aortic contraction, progressive aortic dilation, and
aneurysm formation. MMP-9 is a more potent inhibitor of aortic contraction than MMP-2, consistent with a more
dominant role in AAA. Restoration and preservation of smooth muscle contractile function by specific inhibitors of
MMPs may represent a new strategy in preventing the progression of small AAA.Abdominal aortic aneurysm (AAA) is a focal dilatation
of the aorta that is commonly observed in elderly persons.
The prevalence of AAA has increased dramatically over the
past 3 decades, in part because of the demographic distri-
bution shifting to more elderly persons in the general
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doi:10.1016/j.jvs.2004.08.035population.1,2 AAA is a progressive degenerative disease
that if left uncorrected can result in aortic rupture and
death. Although large AAAs can be repaired surgically, no
effective treatment is currently available for small AAAs,
other than careful observation until they become critically
large and the risk for rupture outweighs the risks of surgery.
Understanding the mechanisms of AAA formation would
help identify new treatment strategies to retard the progres-
sive growth of small AAAs.
Matrix metalloproteinases (MMPs) are a family of
structurally related, zinc-containing enzymes known to
degrade the connective tissue matrix.3-5 MMPs have key
roles in tissue remodeling and cellular migration, and act as
regulatory molecules, both by functioning in enzyme cas-
cades and by processing matrix proteins and adhesion mol-
ecules.3,4,6 Increased MMP activity has been reported in
various inflammatory, malignant, and degenerative disor-
ders, including AAA, and increased MMP production or
decreased expression of MMP inhibitors may have a role in
the pathogenesis of AAA.7-9
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aortic wall expression of MMPs is increased in AAA dis-
ease.10-16 Specifically, MMP-2 (gelatinase A) and MMP-9
(gelatinase B) seem to have an important role in aneurysm
formation.17-23 For example, targeted gene disruption of
MMP-9 in mice suppresses development of experimental
AAAs.24 Also, both MMP-2 and MMP-9 are necessary to
induce experimental AAA formation in mice.22 Because of
their potent elastolytic activity, the mechanism of action of
MMPs in aneurysm formation has largely been attributed
to their proteolytic effects on the extracellular matrix pro-
teins and subsequent weakening of the aortic wall.8,9 Re-
cent studies have suggested that elastolytic enzymes, such
as porcine pancreatic elastase, could have additional effects
on other vascular cell types, and thereby could affect aortic
contraction.25,26 Despite the potent elastolytic activity of
MMPs, little is known about the effects of MMPs on other
vascular cell types, particularly on the mechanisms of aortic
smooth muscle contraction.
Vascular smooth muscle contraction in response to
vasoconstrictor agonists such as phenylephrine is triggered
by an increase in intracellular Ca2 due to Ca2 release
from the intracellular stores and Ca2 entry from the
extracellular space.27 The purpose of this study was to test
the hypothesis that MMPs promote aortic dilation by in-
hibiting the Ca2 mobilization mechanisms of smooth
muscle contraction. Experiments were designed to investi-
gate whether MMPs inhibit phenylephrine-induced aortic
smooth muscle contraction, and whether MMP-induced
inhibition of aortic contraction is due to inhibition of the
Ca2 release mechanism from the intracellular stores or the
Ca2 entry mechanism from the extracellular space. The
effects of MMPs on phenylephrine-induced contraction
and 45Ca2 influx were measured. To further investigate
the Ca2 mobilization mechanism involved, the effects of
MMPs on phenylephrine-induced contraction in Ca2-free
Krebs solution, which is mainly due to Ca2 release from
the intracellular stores, were compared with their effects on
high potassium chloride (KCl)–induced contraction, which
is mainly due to Ca2 entry from the extracellular space.
METHODS
Tissue preparation. Male Sprague-Dawley rats
(Charles River Laboratories), 12 weeks of age andweighing
200 to 300 g, were housed in the animal facility and
maintained on ad libitum standard rat chow and tap water
in a 12-hour light, 12-hour dark cycle. The rats were
euthanized with carbon dioxide inhalation, and complete
euthanasia was judged by cessation of breathing and heart-
beat. The abdominal cavity was opened, and the abdominal
aorta was rapidly excised and placed in oxygenated Krebs
solution.
The aorta was dissected and cleaned of adipose and
connective tissue under microscopic visualization, then cut
into 3-mm-wide strips. The effects of MMP on aortic
contraction could be due to an effect on the endothelium
or direct effects on vascular smooth muscle. To avert the
contribution of the endothelium to the vascular responsesto MMP and to focus mainly on the direct effects of MMP
on vascular smooth muscle, the endothelium was removed
by gently rubbing the vessel interior with wet filter paper.
Removal of the endothelium was routinely verified by the
absence of acetylcholine-induced relaxation in vascular
strips pre-contracted with phenylephrine (3  10-7 mol/
L). All procedures were performed under the guidelines of
the Institutional Animal Care and Use Committee.
Isometric contraction. One end of the aortic strip
was attached to a glass hook with a thread loop, and the
other end was connected to a Grass force transducer
(FT03). Aortic strips were stretched to Lmax (1.5 times
unloaded initial length, L). The strips were allowed to
equilibrate for 1 hour in a water-jacketed, temperature-
controlled tissue bath filled with 25 mL of Krebs solution
continuously bubbled with 95% oxygen and 5% carbon
dioxide at 37oC. The changes in isometric contraction were
recorded on a Grass polygraph (Model 7D; Astro-Med).
A control contraction was elicited by applying 96
mmol/L of KCl to the tissue bath solution. Once the KCl
contraction reached a plateau, the tissue was rinsed with
Krebs solution 3 times for 10 minutes each. The whole
procedure of KCl contraction and washing was repeated
twice.
Aortic strips were stimulated with phenylephrine (105
mol/L) until the contraction reached a plateau, then
treated with varying concentrations of MMP-2 or MMP-9
(0.01-1 g/mL), and changes in phenylephrine contrac-
tion were observed. The tissues were thoroughly rinsed
with Krebs solution 4 times for 15 minutes each. The
tissues were then re-stimulated with phenylephrine (105
mol/L) to determine the reversibility of the inhibitory
effects of MMP. To determine whether the effects of MMP
are specific only to phenylephrine and -adrenergic recep-
tors, the effects of MMP on prostaglandin F2 (PGF2)-
induced contraction were also studied.
In another set of experiments the vascular strips were
incubated for 2 minutes in Ca2-free (2 mmol/L ethylene
glycol bis[-aminoethylether]-N,N,N=,N=-tetra-acetic acid;
EGTA) Krebs solution, then treated with phenylephrine
(105mol/L) to stimulateCa2 release from the intracellular
stores and elicit a first phenylephrine contraction. The tissue
was washed 4 times for 15 minutes each with normal Krebs
solution to replenish the intracellular Ca2 stores, and were
incubated in the presence of MMP-2 or MMP-9 (1 g/mL)
for 1 hour. The bathing medium was changed to Ca2-free
Krebs solution, and the tissue was stimulated with phenyleph-
rine (105 mol/L) to elicit a second contraction. The second
phenylephrine contraction was then compared with the first
(control) phenylephrine contraction.
In other experiments aortic strips were stimulated with
96 mmol/L of KCl, which causes membrane depolariza-
tion and stimulates Ca2 entry from the extracellular
space.27 Once the KCl response reached a plateau, the
tissue strips were treated with MMP-2 or MMP-9 (1 g/
mL), and changes in KCl contraction were observed. The
aortic strips were thoroughly rinsed 4 times for 15 minutes
each with Krebs solution, then re-stimulated with 96
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MMP.
45Ca2 influx. Vascular strips were incubated in
Krebs solution, then stimulated with phenylephrine (105
mol/L) or 96 mmol/L of KCl for 10 minutes in the
absence or presence of MMP-2 or MMP-9 (1 g/mL).
The tissues were transferred to the respective radioactive
45Ca2-labeled solution (specific activity, 5 Ci/mL;
ICN) for 90 seconds. Preliminary experiments have shown
that the relationship between 45Ca2 uptake versus time is
linear during exposure to the 45Ca2 label for15, 30, 60,
and 90 seconds. The tissues were transferred to ice-cold
Ca2-free Krebs solution for 45 minutes to quench extra-
cellular 45Ca2 label. The vascular strips were weighed, and
placed in 2 mL of hypotonic (5 mmol/L) ethylenediamine
tetraacetic acid for 24 hours at 4oC to disrupt the cell
membranes and release the intracellular content of 45Ca2.
The next day, 4 mL of Ecolite scintillation cocktail was
added, and the samples were counted in a liquid scintilla-
tion counter (Packard 1500).
Histologic studies. Aortic strips were stimulated with
phenylephrine (10 5 mol/L) for 10 minutes, then either
treated or not treated with MMP-2 or MMP-9 (1 g/mL)
for 1hour.The tissueswere fixedovernight in freshly prepared
neutral buffered formalin (10%), embedded in paraffin, sec-
tioned (5-m thick), and placed on glass slides. Tissue sec-
tions were prepared for staining with hematoxylin-eosin or
Verhoeff stain for elastin to assess for integrity of the smooth
muscle layer, the extracellular matrix, and elastin in the vessel
wall.
Solutions, drugs and chemicals. Normal Krebs solu-
tion contained NaCl, 120 mmol/L; KCl, 5.9 mmol/L;
NaHCO3, 25 mmol/L; NaH2PO4, 1.2 mmol/L; dex-
trose, 11.5 mmol/L; MgCl2, 1.2 mmol/L; and CaCl2, 2.5
mmol/L, at pH 7.4. For Ca2-free Krebs solution, CaCl2
was omitted and EGTA (2 mmol/L) was added. Solution
of 96mmol/LKCl was prepared as for Krebs solution, with
substitution of KCl for NaCl. Phenylephrine and PGF2
were obtained from Sigma. MMP-2 and MMP-9 (Biomol)
were not the whole molecules, but the active catalytic
subunit of the respective enzyme cloned from human com-
plementary DNA. The specific activities of MMPs were
confirmed with the colorimetric thiopeptolide Ac-Pro-
Leu-Gly-S-Leu-Leu-Gly-Oet as substrate. All other chem-
icals were of reagent grade or better.
Statistical analysis. Data were analyzed and expressed
as mean  SEM. Data were compared with the Student t
test for unpaired and paired data. Percentage changes in
data were analyzed with the Mann-Whitney U test and
EPISTAT statistical program. Differences were considered
statistically significant at P  .05.
RESULTS
Effect of MMP-2 and MMP-9 on Phe contraction
in Ca2-containing solution. In normal Krebs solution
(2.5 mmol/L Ca2), phenylephrine (105 mol/L) caused
a significant contraction that reached a steady state in
approximately 10 minutes. The phenylephrine contractionwas maintained with no significant decline for at least 30
minutes (Fig 1, A). The phenylephrine contraction was
reproducible. After washing the tissue with normal Krebs
solution for 1 hour a second phenylephrine contraction was
not significantly different from the first (control) phenyl-
ephrine contraction (Fig 1, A). Application of MMP-2 (1
g/mL) caused significant inhibition of the phenyleph-
rine-induced contraction (Fig 1, B; and Fig 2). In a similar
fashion, application of MMP-9 (1 g/mL) also caused
significant inhibition of the phenylephrine-induced con-
traction (Fig 1, C; and Fig 2). MMP-9 showed a greater
inhibitory effect on phenylephrine-induced aortic contrac-
tion when compared with MMP-2 (Figs 1 and 2). In
control experiments in which phenylephrine and the
MMPs were placed together before adding to the strips the
initial phenylephrine contraction was not significantly af-
Fig 1. Inhibition of phenylephrine (Phe) contraction by matrix
metalloproteinases MMP-2 and MMP-9. Aortic strips were incu-
bated in normal Krebs solution (2.5 mmol/L Ca2), then stimu-
lated with phenylephrine (105 mol/L). When the phenylephrine
contraction reached a plateau, tissue was either not treated (A) or
treated with 1 g/mL of MMP-2 (B) or MMP-9 (C), and
inhibition of phenylephrine contraction was observed. Tissues
were washed (W)with Krebs solution 4 times for 15 minutes each,
and a second phenylephrine contraction was elicited to determine
reversibility of the effects ofMMPs. Tracings represent results from
5 nontreated 4 MMP-2-treated and 4 MMP-9- treated vascular
strips from different rats.fected; however, the maintained phenylephrine contraction
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to that observed with topical application of MMP on phen-
ylephrine contraction. These control experiments suggest
that the observed inhibitory effects of MMPs are not due to
direct phenylephrine and MMP interaction.
The reversibility of the inhibitory effects ofMMP-2 and
MMP-9 on phenylephrine-induced aortic contraction was
tested. In tissues treated with MMP-2 and MMP-9 (1
g/mL) for 1 hour, followed by rinsing with Krebs solu-
tion for 1 hour, the inhibitory effects of MMP-2 and
MMP-9 on phenylephrine-induced contraction were re-
Fig 2. Reversibility of matrix metalloproteinase (MMP)–induced
inhibition of phenylephrine contraction. Aortic strips were incu-
bated in normal Krebs solution, then stimulated with phenyleph-
rine (105 mol/L). The tissues were either not treated (A) or
treated for 1 hour with 1 g/mL of MMP-2 (B) or MMP-9 (C).
Tissues were washed with Krebs solution 4 times for 15 minutes
each, and a second phenylephrine contraction was elicited and
presented as percentage of control phenylephrine contraction.
Data bars represent mean SEMofmeasurements in 5 nontreated
4 MMP-2-treated and 4 MMP-9-treated vascular strips from dif-
ferent rats. *Significantly different (P .05) from control phenyl-
ephrine contraction, or phenylephrine contraction in tissues stim-
ulated in parallel with phenylephrine for the same period of time
but not treated with MMP (A).versible (Figs 1 and 2). In these tissues the second phenyl-ephrine contraction was not significantly different com-
pared with the first (control) phenylephrine contraction.
Inhibition of phenylephrine contraction by MMP-2
and MMP-9 was dependent on time and concentration
(Fig 3). At 1 g/mL of MMP-2, inhibition of phenyleph-
rine contraction was slow in onset (18.8  3.2 minutes; n
	 4), and maximum inhibition was 48.9%  5.0%. At 1
g/mL of MMP-9, inhibition of phenylephrine contrac-
tion was also slow in onset (20.0 3.5minutes; n	 4), but
maximum inhibition was significantly greater (69.8% 
Fig 3. Matrix metalloproteinase (MMP)–induced inhibition of
phenylephrine contraction is time-dependent and concentration-
dependent. Aortic strips were stimulated with phenylephrine
(105 mol/L), then treated with MMP-2 or MMP-9 (0.01-1
g/mL). A, To illustrate that the effects of MMP were time-
dependent, inhibition of phenylephrine contraction in response to
MMP-2 or MMP-9 (1 g/mL) was measured at different times.
B, To illustrate that the effects of MMP were concentration-
dependent, inhibition of Phe contraction after 1 hour was com-
pared for different concentrations of MMP-2 and MMP-9. For
each concentration of MMP, 4 vascular strips from different rats
were used. Data are presented as mean  SEM. *Significantly
different (P  .05) from control phenylephrine contraction.6.2%) than that induced by MMP-2 (P 	 .039).
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cific only to phenylephrine and -adrenergic receptors, we
tested the effect of MMP-9 on PGF2 (10
5 mol/L)–
induced aortic contraction. MMP-9 (1 g/mL) caused
68.5% inhibition of PGF2-induced contraction.
Effect of MMPs on aortic wall structure. To deter-
mine whether treatment with MMP-2 or MMP-9 caused
disruption of the structural integrity of the vessel wall or
degradation of elastin, tissue sections were prepared for
histologic examination with hematoxylin-eosin stain and
Verhoeff stain for elastin. Tissue sections of the control
aorta showed an intact tunica media and preserved elastin
layer. In tissues treated with either MMP-2 or MMP-9 (1
g/mL) for 1 hour the tunica media remained intact and
no significant elastin degradation was seen, compared with
control tissue (Fig 4). The aortic media–total wall thickness
was 57.9%  0.7% in nontreated vessels, which was not
significantly different (P
 .06) from that in vessels treated
with MMP-2 (60.1% 1.7%; n	 5) or MMP-9 (60.9%
Fig 4. Effect of matrix metalloproteinase (MMP) on str
treated for 1 hour with 1 g/mL of MMP-2 or MMP-9.
eosin (left panels) or Verhoeff stain for elastin (right panel
differences were found at subjective examination of MM1.9%; n 	 5).Effect of MMPs on aortic contraction in Ca2-free
solution. Agonist-induced contraction in Ca2-free solu-
tion represents the Ca2 entry-independent mechanisms of
vascular contraction, and is often used as a measure of Ca2
release from the intracellular Ca2 stores in the smooth
muscle sarcoplasmic reticulum.27 In Ca2-free (2 mmol/L
of EGTA) Krebs solution phenylephrine (105 mol/L)
caused a small contraction. The aortic strips were rinsed
with normal Krebs solution for 1 hour to replenish the
intracellular Ca2 stores, and then a second phenylephrine
contraction was elicited in Ca2-free Krebs solution. In
control experiments the second phenylephrine contraction
did not appear to be different from the first phenylephrine
contraction (Fig 5, A). In tissues treated with MMP-2 or
MMP-9 (1 g/mL) for 1 hour the second phenylephrine
contraction was not different from the first phenylephrine
contraction, which suggests preservation of the intracellu-
lar Ca2 release mechanism (Fig 5, B and C).
Effect of MMPs on KCl contraction. Membrane
e of rat aorta. Rat aortic strips were either nontreated or
e sections were prepared and stained with hematoxylin-
shed lines indicate different layers of vessel. No structural
ated and MMP-nontreated vessels.uctur
Tissu
s).Da
P-tredepolarization with 96 mmol/L of KCl, which stimulates
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contraction, which reached a plateau in approximately 10
minutes. TheKCl contractionwas completely inhibited by the
Ca2 channel blocker verapamil (105 mol/L), confirming
that the KCl contraction is mainly due toCa2 entry from the
extracellular space. MMP-2 andMMP-9 caused inhibition of
the KCl-induced aortic contraction that was slow in onset
(13.3 6.0 minutes, n	 3; and 12.9 1.5 minutes, n	 7)
and time-dependent. The inhibitory effects of MMPs on
KCl-induced contraction were completely reversible, and a
second KCl contraction was not significantly different from
the first (control) KCl contraction (Fig 6).
Effect of MMPs on 45Ca2 influx. Phenylephrine
(105 mol/L) and 96 mmol/L of KCl caused significant
increase in 45Ca2 influx in control aortic strips. In tissues
treated with MMP-2 or MMP-9 (1 g/mL), phenyleph-
rine-induced and KCl-induced 45Ca2 influx were signifi-
cantly reduced compared with control tissues (Fig 7).
DISCUSSION
The main findings of the present study are that MMP-2
Fig 5. Effect of matrix metalloproteinase (MMP) on phenyleph-
rine-induced contraction in Ca2-free Krebs solution. Aortic strips
were incubated for 2 minutes in Ca2-free (2 mmol/L ethylene
glycol bis[-aminoethyl ether]-N,N,N=,N=-tetraacetic acid) Krebs
solution, then treated with phenylephrine (105 mol/L) to stim-
ulate Ca2 release from the intracellular stores and elicit a first
contraction. Tissue was washed with normal Krebs solution for 1
hour to replenish intracellular Ca2 stores, then incubated in the
absence (A) or presence of 1 g/mL of MMP-2 (B) or MMP-9
(C). Bathing medium was changed to Ca2-free Krebs solution,
and a second phenylephrine contraction was elicited and compared
with the first phenylephrine contraction.and MMP-9 reversibly inhibit phenylephrine-induced aor-tic contraction; MMP-2 and MMP-9 treatment does not
inhibit phenylephrine-induced contraction in Ca2-free
Krebs solution, which is a measure of Ca2 release from the
intracellular stores; MMP-2 and MMP-9 treatment inhibit
KCl-induced contraction, and phenylephrine-induced and
KCl-induced 45Ca2 influx; and MMP-9 is a more potent
inhibitor of aortic contraction than MMP-2 is.
To our knowledge, no previous studies have examined
the effects of MMP on vascular smooth muscle contraction
or relaxation. The inhibitory effects of MMPs on phenyl-
ephrine-induced aortic contraction could be due to an
effect on the endothelium, the connective tissue matrix, or
the smooth muscle. Because in the in vivo conditions the
endothelium is present on the aortic wall, at least in the
initial stages of aneurysm development, the effects of MMP
on aortic contraction could be due to an effect on the
endothelium. For example, the vascular endothelium re-
leases endothelium-dependent relaxing factors, such as ni-
tric oxide, and thereby cause smooth muscle relaxation.
However, it is unlikely that the observed inhibition of
vascular contraction is due to an effect of MMPs on endo-
thelium-derived relaxing factors, because the present ex-
periments were performed on endothelium-denuded vas-
cular strips. Another possibility is that MMPs may cause
elastin degradation and disruption of the connective tissue
matrix, which could decrease the ability of the blood vessel
to maintain contraction. However, the present histologic
studies showed no evidence of extracellular matrix destruc-
tion in tissues treated with MMP-2 or MMP-9 at the
concentrations and relatively short duration of treatment
tested. Also, the complete reversibility of the effects of
MMPs on phenylephrine-induced and KCl-induced con-
traction and the lack of effect of MMPs on phenylephrine-
induced contraction in Ca2-free Krebs solution suggest
that the inhibitory effects of MMPs are not solely due to
irreversible degradation of the extracellular matrix. It also
appears unlikely that the inhibitory effects ofMMPs are due
to an effect on phenylephrine or -adrenergic receptors,
because MMPs did not inhibit phenylephrine contraction
in Ca2-free solution. Furthermore, MMPs inhibited
PGF2-induced contraction, which suggests that the inhib-
itory effects of MMPs are not specific to a particular agonist
or receptor, but more likely involve direct effects of MMPs
on a common signaling mechanism of vascular smooth
muscle contraction downstream from receptor activation.
Vascular smooth muscle contraction is triggered by an
increase in intracellular Ca2 due to Ca2 release from the
intracellular stores and Ca2 entry from the extracellular
space.27 The observation that MMPs did not inhibit phen-
ylephrine-induced contraction in Ca2-free Krebs solution
suggests that the MMPs may not work by inhibiting the
Ca2 release mechanism from the intracellular stores. On
the other hand, the observations that MMPs inhibit KCl-
induced contraction and the phenylephrine-induced and
KCl-induced 45Ca2 influx suggest that they may function
by inhibiting Ca2 entry from the extracellular space.
The specific mechanism by which the MMPs inhibit
Ca2 entry is unclear, but could be related to possible
tract
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Fig 6. Matrix metalloproteinase (MMP)-induced inhib
were stimulated with 96 mmol/L of KCl, then treated wi
inhibition of KCl contraction was observed. Tissues were
a second KCl contraction was elicited to determine the re
contraction was then presented as percent of control 96 m
of measurements in 5 vascular strips treated with MMP
different (P  .05) from control 96 mmol/L of KCl con
Fig 7. Basal, phenylephrine (105 mol/L)–induced, and potas-
sium chloride (KCl; 96 mmol/L)–induced 45Ca2 influx in aortic
strips nontreated or treated with 1 g/mL of matrix metallopro-
teinase (MMP) MMP-2 or MMP-9. Data bars represent mean 
SEM of measurements in 5 vascular strips. *Phenylephrine-in-
duced Ca2 influx is significantly less (P  .05) in MMP-treated
compared with nontreated strips. †KCl-induced Ca2 influx is
significantly less (P  .05) in MMP-treated compared with non-
treated strips.also cause degradation of collagen and produce Arg-Gly-Asp–containing peptides, which bind to v3 integrin re-
ceptors and inhibit Ca2 entry in vascular smooth mus-
cle.28-31 MMPs may also interact with specific cell surface
proteins, such as intercellular adhesion molecule–1, or
stimulate protease-activated receptors and activate signal-
ing pathways, which could lead to blockade of smooth
muscle Ca2 channels.32-34 This is supported by reports
that proteases such as thrombin could activate protease-
activated receptors and cause vascular smoothmuscle relax-
ation by inhibiting Ca2 influx.35 The greater inhibitory
effects of MMP-9 compared with MMP-2 could be due to
greater affinity to the Ca2 channels or to other modulat-
ing molecules such as integrins and protease-activated re-
ceptors. Further studies are needed to define the role of
integrins and protease-activated receptors as possible mo-
lecular mechanisms by which MMPs could inhibit Ca2
entry into vascular smooth muscle.
We have observed that MMPs cause greater inhibi-
tion of phenylephrine-induced contraction than KCl-
induced contraction. Inasmuch as KCL contraction is
mainly due to Ca2 entry,27 the greater inhibition of
phenylephrine by MMPs could be due to inhibition of
other signaling mechanisms of vascular contraction, such
as protein kinase C, Rho-kinase, or mitogen-activated
protein kinase, and should represent important areas for
of potassium chloride (KCl) contraction. Aortic strips
g/mL ofMMP-2 (A andC) or MMP-9 (B andD), and
ed with Krebs solution 4 times for 15 minutes each, and
ility of MMP-induced inhibition.C andD, Second KCl
L of KCl contraction. Data bars represent mean SEM
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inhibitory effects of MMPs on the mechanisms of vascular
contraction could be reversed by MMP inhibitors, such as
MMP-2 or MMP-9 inhibitor IV and 2-macroglobulin.
These MMP inhibitors exerted an inhibitory effect on
vascular smooth muscle contraction (data not shown).
These MMP inhibitors have a Zn2 binding site, and
therefore could bind Zn2 ion or other divalent cations
such as Ca2. Therefore it is likely that these MMP inhib-
itors bind extracellular Ca2, and thereby would confound
the present results. Future studies should determine
whether the inhibitory effects of MMPs on vascular con-
traction are reversed by other MMP inhibitors, such as
tissue inhibitor of metalloproteinases (TIMP), TIMP-1 or
TIMP-2.
We have considered performing control experiments
with an MMP that has not been shown to be present in
aortic aneurysm. However, the list of MMPs that could
have a role in AAA formation is growing, and includes, in
addition to MMP-2 and MMP-9, MMP-1, MMP-3,
MMP-7, MMP-8, and MMP-12.16,36-38 The focus of the
present study was to understand the mechanism of MMP-
induced inhibition of aortic smooth muscle contraction.
Comparison of the effects of MMP-2 and MMP-9 with
several other MMPs less described in AAA could be the
subject of future comparative studies. An excellent control
experiment would be with an MMP that is least likely to
have a role in AAA, such as the tooth enamel MMP-20
(enamelysin), and as it becomes commercially available it
will be a useful tool for control experiments in future
studies.
The observed effects of MMPs on the mechanisms of
aortic smooth muscle contraction could be of importance
in the pathogenesis of AAAs. Increased expression of
MMPs is often found in tissue samples from the aneurysm
wall.10-12,16,17 The median concentration of MMP-2 in
AAA wall is 0.04 g/mL,39 and that of MMP-9 is 0.5
g/g of tissue weight.40 Also, the levels of MMP-2 and
MMP-9 isolated from fibroblasts and smooth muscle cells
cultured from AAA wall are between 0.01 and 1.2 g/
mL.19 Furthermore, patients with AAA have elevated
plasma levels of MMP-2 and MMP-9, in the range of 0.06
to 0.6 g/mL.13,14,41 MMP-2 has the greatest elastolytic
activity, and is produced mainly by smooth muscle and
fibroblasts.42,43 MMP-9 is the most abundantly expressed
MMP in AAA tissue, and is produced mainly by aneurysm-
infiltrating macrophages.11,18,36 Although degradation of
the extracellular matrix by MMPs could have a significant
role in the pathogenesis of AAA, the present data show an
additional novel effect of MMP-2 and MMP-9 on the
Ca2-entry mechanisms of vascular smooth muscle con-
traction that may also contribute to AAA formation. For
example, the inhibitory effects of the MMPs on aortic
smooth muscle contraction were observed at concentra-
tions similar to those observed in plasma and tissue samples
from patients with AAA. Also, the observed MMP-induced
inhibition of aortic smooth muscle contraction occurred
even in the absence of degradation of the connective tissuematrix of the vessel wall. Furthermore, the present data
show that MMP-9 is a more potent inhibitor of aortic
contraction than MMP-2 is, consistent with the observa-
tions that MMP-9 is the dominant MMP in AAA
wall.11,18,23,36,44
The extracellular matrix proteins elastin and collagen
provide significant structural support of the aorta. On the
other hand, the contribution of vascular smooth muscle
contraction to the overall tensile strength of the aortic wall
is less clear. There is evidence, however, to suggest that the
integrity of aortic smooth muscle contractile function may
contribute to the structural integrity of the aortic wall.
First, the tunica media composes a major portion of the
aortic wall, and is formed mainly of circumferentially ar-
ranged alternating lamellae of smooth muscle cells and
elastin fibers. An active and tonic contraction of the smooth
muscle is predicted to limit the tendency of the aorta to
dilate in response to pulsatile forces generated with each
cardiac cycle. Second, atrophy of the tunica media and
depletion or apoptosis of smoothmuscle cells are consistent
histologic findings in AAA.45,46 Third, disruption of the
structural integrity of the tunica media, for example, in
chronic aortic dissection, often leads to late aneurysm for-
mation. Thus the MMP-induced inhibition of vascular
smooth muscle contraction could function synergistically
with their degradation of the extracellular matrix, and
thereby contribute to further weakening of the aortic wall
and aneurysm formation.
In the present study we tested the acute in vitro effects
of MMPs on vascular function. The acute effects of MMPs
on aortic contraction were reversible at the concentrations
and duration of treatment tested. It remains to be examined
whether the acute inhibitory effects of MMPs on smooth
muscle contraction represent an early event in AAA forma-
tion. However, the effects of MMPs may be different in
vivo, where an initial MMP insult could initiate a cascade of
events leading to progressive smooth muscle dysfunction
and cell death. Also, because AAA is a slow and progressive
disease, prolonged exposure to MMPs may lead to pro-
tracted inhibition of the Ca2-entry mechanisms of aortic
smooth muscle contraction. This prolonged inhibition of
vascular contraction may contribute to progressive aortic
dilation and aneurysm formation over time. Therefore the
effects of prolonged exposure to MMPs on smooth muscle
function, both in vitro and in vivo, should be examined in
future studies. We should mention that the present study
tested the effects of MMPs on aortic smooth muscle in
normotensive rats. Future studies should examine the ef-
fects ofMMPs on vascular smoothmuscle of animal models
of hypertension, because the relation between vessel tonic-
ity and diastolic hypertension could be a factor in aneurysm
formation in human beings.
In conclusion, the present data suggest that MMP-2
and MMP-9 inhibit the Ca2 entry mechanisms of aortic
smooth muscle contraction, and may further explain the
role of increasedMMP activity during early development of
AAA.MMP-9 is a more potent inhibitor of the mechanisms
of vascular contraction than MMP-2 is, consistent with
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 5 Chew, Conte, and Khalil 1009experimental evidence in mice of its dominant role in AAA
formation.
We acknowledge the assistance and expertise of Ms
Sandra Zapatka-Taylor in tissue sectioning and staining for
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